HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >

Fulvestrant 500 mg in postmenopausal patients with metastatic breast cancer : the initial clinical experience

Files in This Item:
BreastCancer23_617.pdf401.48 kBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/66413

Title: Fulvestrant 500 mg in postmenopausal patients with metastatic breast cancer : the initial clinical experience
Authors: Ishida, Naoko Browse this author
Araki, Kazuhiro Browse this author
Sakai, Takehiko Browse this author
Kobayashi, Kokoro Browse this author
Kobayashi, Takayuki Browse this author
Fukada, Ippei Browse this author
Hosoda, Mitsuchika Browse this author →KAKEN DB
Yamamoto, Mitsugu Browse this author
Ichinokawa, Kazuomi Browse this author
Takahashi, Shunji Browse this author →KAKEN DB
Iwase, Takuji Browse this author
Ito, Yoshinori Browse this author →KAKEN DB
Yamashita, Hiroko Browse this author →KAKEN DB
Keywords: Fulvestrant
Metastatic breast cancer
Advanced breast cancer
Postmenopausal
Endocrine therapy
Issue Date: Jul-2016
Publisher: Springer
Journal Title: Breast cancer
Volume: 23
Issue: 4
Start Page: 617
End Page: 623
Publisher DOI: 10.1007/s12282-015-0612-0
PMID: 25896598
Abstract: Background: Fulvestrant 500 mg is currently approved for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer after failure of prior endocrine therapies. Methods: A total of 117 postmenopausal women with metastatic breast cancer, who experienced progression after previous endocrine therapies, were treated with fulvestrant 500 mg between January 2012 and June 2014. Clinical response, time to progression (TTP) and adverse events were investigated. Results: Ninety-nine patients had recurrent breast cancer and 18 patients had stage IV disease. Patients had received a median of two endocrine therapies and a median of two chemotherapies, prior to fulvestrant. There were 10 patients with partial response, 39 patients with long stable disease, 18 patients with stable disease, and 50 patients with progressive disease, so that the objective response rate was 8.5 %, with a clinical benefit rate of 41.9 %. The median TTP was 6.1 months. The absence of liver metastases, a small number of previous chemotherapies, and the longer duration of first-line endocrine therapy were positively correlated with TTP in univariate analysis. In multivariate analysis, a significant association was observed between TTP and duration of first-line endocrine therapy. Serious adverse events were observed in one patient with pulmonary embolism and in one patient with psychiatric symptoms. Conclusions: Fulvestrant 500 mg is an effective and well-tolerated treatment for postmenopausal women with metastatic breast cancer that had progressed after prior endocrine therapies. Patients with acquired resistance to endocrine therapies might be good candidates for fulvestrant therapy regardless of the number of prior endocrine treatments.
Rights: The final publication is available at link.springer.com
Type: article (author version)
URI: http://hdl.handle.net/2115/66413
Appears in Collections:北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 山下 啓子

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 

 - Hokkaido University